RxDoctor Payments Data

Joy Dodson, APRN

Family · Foreman, ARNPI 1972194678

Payments from drug & device makers

$390in general payments, 2019–2025

Across 20 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$148
  • Abbott$78
  • GSK$69
  • Lilly USA, LLC$50
  • Astellas Pharma US Inc$18
  • AbbVie$13
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$390100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca9$148
Abbott1$78
GSK4$69
Lilly USA, LLC3$50
Astellas Pharma US Inc1$18
AbbVie1$13
Pfizer1$13

How this compares

$390 in reported general payments places this provider in the 50th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$45,733
Medicare patients
227
Services billed
1,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide87$93,739
OzempicSemaglutide57$85,049
EliquisApixaban61$66,025
FarxigaDapagliflozin Propanediol53$54,033
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$47,940
LinzessLinaclotide58$32,546
JardianceEmpagliflozin23$29,629
TrulicityDulaglutide16$18,482
EntrestoSacubitril/Valsartan12$15,077
MyrbetriqMirabegron11$14,814
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$14,762
Albuterol Sulfate HfaAlbuterol Sulfate116$3,233
Gabapentin164$2,958
Clonidine12$2,371
Omeprazole103$1,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$50$112,221103 claims
AstraZenecaFarxiga, Breztri Aerosphere$148$68,79474 claims
PfizerEliquis$13$66,02561 claims
GSKTrelegy Ellipta$69$47,94071 claims
AbbVieLinzess, Synthroid$13$33,09669 claims
Astellas Pharma US IncMyrbetriq$18$14,81411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,103 family providers in Arkansas.

Other family in Foreman

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →